Non-Hormonal Treatments for Genitourinary Syndrome of Menopause

Genitourinary syndrome of menopause (GSM), the term for vaginal atrophy and related urinary symptoms, affects up to half of postmenopausal women. For many, symptoms like dryness, burning, and urinary incontinence persist for decades, significantly impacting quality of life. While estrogen therapy is effective, not all women can or wish to use it, creating a need for diverse, evidence-backed options. New research, including a 2026 clinical trial from Brazil, is evaluating non-hormonal approaches that work by stimulating the body’s own repair mechanisms.

Photobiomodulation: A Light-Based Approach Shows Promise for Incontinence

A 2026 randomized, double-blind clinical trial from researchers at Universidade Nove de Julho in São Paulo tested a novel technology for GSM. The team, led by Pereira SRDS, investigated photobiomodulation (PBM) therapy, which uses low-level laser or light-emitting diode (LED) light to stimulate cellular function. In this study, 65 postmenopausal women with GSM received either real PBM or a placebo treatment over four weekly sessions.

The treatment protocol applied an 808 nm laser to eight specific vaginal points for 40 seconds each. This wavelength penetrates tissue and is absorbed by cellular components called mitochondria, thought to boost energy production and reduce inflammation. Results showed a significant reduction in urinary loss for the PBM group compared to placebo, measured by a standard incontinence questionnaire. Participants also reported subjective improvements in vaginal dryness and burning. However, the therapy did not produce significant changes in pelvic pressure or sexual function scores. This suggests PBM may be most effective for specific GSM components, particularly urinary symptoms and some vulvovaginal discomfort.

Personalizing the Path to Relief: A Modern Management Framework

The “one-size-fits-all” approach to GSM is fading. A 2026 review from Mayo Clinic specialists Cyriac and Sood emphasizes that effective management starts with a thorough assessment, including a detailed history and physical exam to rule out other conditions. Treatment selection is then guided by symptom severity, the patient’s overall health profile, and personal choice.

For women with moderate to severe symptoms, low-dose vaginal estrogen remains a highly effective first-line option, with minimal systemic absorption. For those who cannot use estrogen, non-hormonal vaginal moisturizers and lubricants are essential for daily comfort. The review highlights the importance of addressing the sexual health consequences of GSM, which often requires open conversations and may involve referrals to pelvic health physiotherapists or sexual health counselors. This holistic, patient-centered model ensures care extends beyond a prescription to encompass overall well-being.

How New Treatments Target Tissue Health Without Estrogen

Treatments like photobiomodulation represent a shift toward therapies that don’t replace estrogen but instead support the vaginal tissue’s inherent ability to maintain itself. The lining of the vagina is rich in collagen, blood vessels, and moisture-producing cells, all of which depend on estrogen for maintenance. When estrogen declines, these tissues become thinner, drier, less elastic, and more fragile—a process known as atrophy.

PBM and other emerging modalities aim to interrupt this cycle. The proposed mechanism is that light energy absorbed at the cellular level increases mitochondrial activity. This can lead to improved blood flow, enhanced collagen synthesis, and reduced local inflammation. Essentially, it may help “wake up” dormant cellular processes in the genital tissue, improving its structure and function from within. This approach is conceptually different from adding lubrication externally or supplementing hormones, and it offers a complementary strategy for tissue rejuvenation.

Managing GSM is a critical component of long-term health for women in menopause and beyond. The emergence of research on options like photobiomodulation expands the therapeutic landscape, providing new avenues for those seeking non-hormonal solutions. Effective care combines these evolving options with established treatments, all within a framework that prioritizes individual symptoms and preferences. Open dialogue with a healthcare provider is the essential first step toward developing a sustainable, personalized plan for comfort and health.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42060269/
https://pubmed.ncbi.nlm.nih.gov/41892504/